|Dr. Francis E. O'Donnell Jr., M.D.||Exec. Chairman||N/A||N/A||67|
|Dr. Mark A. Sirgo Pharm.D.||Vice Chairman, Chief Exec. Officer and Pres||755.64k||N/A||63|
|Mr. Ernest Robert De Paolantonio CPA, MBA||Chief Financial Officer, Corp. Sec. and Treasurer||457.98k||N/A||64|
|Dr. Niraj Vasisht Ph.D.||Chief Technology Officer and Sr. VP of Product Devel.||416.36k||N/A||53|
|Mr. Albert J. Medwar MBA||Sr. VP of Corp. & Bus. Devel.||N/A||N/A||N/A|
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
BioDelivery Sciences International, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 5; Compensation: 10.